Jazz Pharmaceuticals PLC
JAZZ165.500USD
+2.350+1.44%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
10.05BMarket Cap
LossP/E TTM
More Details of Jazz Pharmaceuticals PLC Company
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC Info
Ticker SymbolJAZZ
Company nameJazz Pharmaceuticals PLC
IPO dateJan 18, 2012
CEOGala (Renee D)
Number of employees2800
Security typeOrdinary Share
Fiscal year-endJan 18
AddressFifth Floor, Waterloo Exchange
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code- -
Phone35316347800
Websitehttps://www.jazzpharma.com/
Ticker SymbolJAZZ
IPO dateJan 18, 2012
CEOGala (Renee D)
Company Executives of Jazz Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+3507.00%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
310.79K
+18464.00%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
55.49K
+7370.00%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
31.68K
+7559.00%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
27.20K
+5577.00%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
13.92K
+1702.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
12.77K
+1702.00%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
11.28K
+2038.00%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
7.11K
+1702.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+3507.00%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
310.79K
+18464.00%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
55.49K
+7370.00%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
31.68K
+7559.00%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
27.20K
+5577.00%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
15.00K
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Xywav
431.41M
38.31%
Epidiolex/epidyolex
302.61M
26.87%
Rylaze
99.87M
8.87%
Zepzelca
79.30M
7.04%
High-sodium oxybate AG royalty revenue
52.95M
4.70%
Other
159.98M
14.21%
By RegionUSD
Name
Revenue
Proportion
United States
1.02B
90.62%
Europe
86.41M
7.67%
All Others
19.23M
1.71%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Xywav
431.41M
38.31%
Epidiolex/epidyolex
302.61M
26.87%
Rylaze
99.87M
8.87%
Zepzelca
79.30M
7.04%
High-sodium oxybate AG royalty revenue
52.95M
4.70%
Other
159.98M
14.21%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.04%
Other
69.14%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
8.25%
Dimensional Fund Advisors, L.P.
4.67%
Capital World Investors
4.20%
LSV Asset Management
4.04%
Other
69.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.47%
Investment Advisor/Hedge Fund
34.46%
Hedge Fund
10.57%
Research Firm
3.49%
Individual Investor
3.09%
Pension Fund
1.75%
Venture Capital
1.30%
Bank and Trust
1.13%
Family Office
0.10%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1196
62.93M
103.56%
-8.99M
2025Q3
1197
64.03M
105.38%
-5.21M
2025Q2
1199
63.76M
105.11%
-6.47M
2025Q1
1235
63.66M
105.15%
-6.35M
2024Q4
1202
62.66M
103.17%
-6.51M
2024Q3
1172
61.48M
99.60%
-6.16M
2024Q2
1167
61.28M
97.21%
-6.97M
2024Q1
1163
63.08M
101.15%
-2.43M
2023Q4
1156
61.76M
98.11%
-3.48M
2023Q3
1158
61.08M
96.76%
-4.05M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
5.88M
9.68%
-184.81K
-3.05%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.01M
8.25%
-208.46K
-3.99%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
2.84M
4.67%
+298.81K
+11.77%
Sep 30, 2025
Capital World Investors
2.55M
4.2%
+10.35K
+0.41%
Sep 30, 2025
LSV Asset Management
2.51M
4.13%
-41.88K
-1.64%
Sep 30, 2025
State Street Investment Management (US)
1.87M
3.07%
-67.50K
-3.49%
Sep 30, 2025
EcoR1 Capital, LLC
1.71M
2.81%
--
--
Sep 30, 2025
JP Morgan Asset Management
1.70M
2.8%
+152.32K
+9.83%
Sep 30, 2025
Fuller & Thaler Asset Management Inc.
1.63M
2.68%
-2.82K
-0.17%
Sep 30, 2025
Columbia Threadneedle Investments (US)
1.57M
2.58%
+29.17K
+1.89%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Cambria Cannabis ETF
4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
3.11%
iShares U.S. Pharmaceuticals ETF
3.08%
Invesco Pharmaceuticals ETF
2.94%
State Street SPDR S&P Pharmaceuticals ETF
2.83%
Abacus FCF International Leaders ETF
2.69%
First Trust NASDAQ Pharmaceuticals ETF
2.51%
Clough Hedged Equity ETF
2.4%
Alger Russell Innovation ETF
2.12%
VictoryShares Small Cap Free Cash Flow ETF
1.77%
View more
Cambria Cannabis ETF
Proportion4.08%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion3.11%
iShares U.S. Pharmaceuticals ETF
Proportion3.08%
Invesco Pharmaceuticals ETF
Proportion2.94%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.83%
Abacus FCF International Leaders ETF
Proportion2.69%
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.51%
Clough Hedged Equity ETF
Proportion2.4%
Alger Russell Innovation ETF
Proportion2.12%
VictoryShares Small Cap Free Cash Flow ETF
Proportion1.77%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
